1. Clinical, neuroimaging and biochemical findings in patients and patient fibroblasts expressing ten novel GFM1 mutations
- Author
-
Giulia Barcia, Agnès Rötig, Pascale de Lonlay, Naïg Gueguen, Manuel Schiff, Marlène Rio, Nathalie Boddaert, Jean-Paul Bonnefont, Arnold Munnich, Pascale Marcorelles, Metodi D. Metodiev, Vincent Procaccio, Zahra Assouline, Isabelle Desguerre, Benedetta Ruzzenente, Marie Hully, Julie Steffann, Abdelhamid Slama, Magalie Barth, Coralie Zangarelli, and Valerie D Dumas
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Mitochondrial translation ,Neuroimaging ,Disease ,Biology ,Mitochondrial Proteins ,03 medical and health sciences ,Basal ganglia ,Databases, Genetic ,Genetics ,medicine ,Image Processing, Computer-Assisted ,Humans ,Genetic Predisposition to Disease ,Genetics (clinical) ,Alleles ,Genetic Association Studies ,030304 developmental biology ,Dystonia ,0303 health sciences ,030305 genetics & heredity ,Brain ,West Syndrome ,Fibroblasts ,medicine.disease ,Peptide Elongation Factor G ,Phenotype ,Magnetic Resonance Imaging ,Mitochondria ,Pedigree ,Gene Expression Regulation ,Mutation ,Female ,Brainstem - Abstract
Pathogenic GFM1 variants have been linked to neurological phenotypes with or without liver involvement, but only a few cases have been reported in the literature. Here, we report clinical, biochemical, and neuroimaging findings from nine unrelated children carrying GFM1 variants, 10 of which were not previously reported. All patients presented with neurological involvement-mainly axial hypotonia and dystonia during the neonatal period-with five diagnosed with West syndrome; two children had liver involvement with cytolysis episodes or hepatic failure. While two patients died in infancy, six exhibited a stable clinical course. Brain magnetic resonance imaging showed the involvement of basal ganglia, brainstem, and periventricular white matter. Mutant EFG1 and OXPHOS proteins were decreased in patient's fibroblasts consistent with impaired mitochondrial translation. Thus, we expand the genetic spectrum of GFM1-linked disease and provide detailed clinical profiles of the patients that will improve the diagnostic success for other patients carrying GFM1 mutations.
- Published
- 2019